Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophages.

In 2001, IFN-γ was used subcutaneously to prevent opportunistic infections (OIs) in HIV-1-infected patients but failed to reach significance due to over dispersion in the model (1.71 OIs for IFN-γ recipients versus 3.45 OIs for controls over 48 months, NS), and had reversible adverse events [9] .

also in 4,113 other papers